These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 32928644)

  • 41. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
    Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
    Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathogenic LRRK2 requires secondary factors to induce cellular toxicity.
    Lobbestael E; Van den Haute C; Macchi F; Taymans JM; Baekelandt V
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32975566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation.
    Pischedda F; Cirnaru MD; Ponzoni L; Sandre M; Biosa A; Carrion MP; Marin O; Morari M; Pan L; Greggio E; Bandopadhyay R; Sala M; Piccoli G
    Brain; 2021 Jun; 144(5):1509-1525. PubMed ID: 33876242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetics of Parkinson's disease: a review of SNCA and LRRK2.
    Konno T; Siuda J; Wszolek ZK
    Wiad Lek; 2016; 69(3 Pt 1):328-32. PubMed ID: 27486710
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reply to: "Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations".
    Macías-García D; Periñán MT; Muñoz-Delgado L; Jesús S; Jimenez-Jaraba MV; Buiza-Rueda D; Bonilla-Toribio M; Adarmes-Gómez A; Carrillo F; Gómez-Garre P; Mir P
    Mov Disord; 2022 May; 37(5):1119-1120. PubMed ID: 35587631
    [No Abstract]   [Full Text] [Related]  

  • 46. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
    Qing H; Wong W; McGeer EG; McGeer PL
    Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Models of LRRK2-Associated Parkinson's Disease.
    Xiong Y; Dawson TM; Dawson VL
    Adv Neurobiol; 2017; 14():163-191. PubMed ID: 28353284
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation.
    Puschmann A; Englund E; Ross OA; Vilariño-Güell C; Lincoln SJ; Kachergus JM; Cobb SA; Törnqvist AL; Rehncrona S; Widner H; Wszolek ZK; Farrer MJ; Nilsson C
    Parkinsonism Relat Disord; 2012 May; 18(4):332-8. PubMed ID: 22154298
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease.
    Sanjari Moghaddam H; Aarabi MH
    Mov Disord; 2018 Dec; 33(12):1876. PubMed ID: 30452792
    [No Abstract]   [Full Text] [Related]  

  • 51. Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus.
    Tatura R; Kraus T; Giese A; Arzberger T; Buchholz M; Höglinger G; Müller U
    Parkinsonism Relat Disord; 2016 Dec; 33():115-121. PubMed ID: 27717584
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Misfolded protein propagation in an integrated computational model of structural network and LRRK2 gene expression.
    Yan W; Ye C; Wang T; Sun J; Wu T; Ma T
    Annu Int Conf IEEE Eng Med Biol Soc; 2020 Jul; 2020():2368-2371. PubMed ID: 33018482
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.
    Vermilyea SC; Emborg ME
    Stem Cells Dev; 2018 Jul; 27(14):960-967. PubMed ID: 29402177
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LRRK2 and the new era of Parkinson's disease research.
    The Lancet Neurology
    Lancet Neurol; 2016 Nov; 15(12):1195. PubMed ID: 27751534
    [No Abstract]   [Full Text] [Related]  

  • 55. The SNCA (A53T, A30P, E46K) and LRRK2 (G2019S) mutations are rare cause of Parkinson's disease in South Indian patients.
    Vishwanathan Padmaja M; Jayaraman M; Srinivasan AV; Srikumari Srisailapathy CR; Ramesh A
    Parkinsonism Relat Disord; 2012 Jul; 18(6):801-2. PubMed ID: 22436655
    [No Abstract]   [Full Text] [Related]  

  • 56. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
    Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
    Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel rare variant of LRRK2 associated with familial Parkinson's disease: p.R1501W.
    Masuzugawa S; Nishioka K; Imai Y; Ogata J; Shojima Y; Li Y; Yoshino H; Hattori N
    Parkinsonism Relat Disord; 2020 Jul; 76():46-48. PubMed ID: 32563051
    [No Abstract]   [Full Text] [Related]  

  • 58. Olfactory Dysfunction in Parkinson's Disease Patients with the LRRK2 G2385R Variant.
    Cao M; Gu ZQ; Li Y; Zhang H; Dan XJ; Cen SS; Li DW; Chan P
    Neurosci Bull; 2016 Dec; 32(6):572-576. PubMed ID: 27699718
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular basis of Parkinson's disease.
    Yang YX; Wood NW; Latchman DS
    Neuroreport; 2009 Jan; 20(2):150-6. PubMed ID: 19151598
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study.
    Wang L; Heckman MG; Aasly JO; Annesi G; Bozi M; Chung SJ; Clarke C; Crosiers D; Eckstein G; Garraux G; Hadjigeorgiou GM; Hattori N; Jeon B; Kim YJ; Kubo M; Lesage S; Lin JJ; Lynch T; Lichtner P; Mellick GD; Mok V; Morrison KE; Quattrone A; Satake W; Silburn PA; Stefanis L; Stockton JD; Tan EK; Toda T; Brice A; Van Broeckhoven C; Uitti RJ; Wirdefeldt K; Wszolek Z; Xiromerisiou G; Maraganore DM; Gasser T; Krüger R; Farrer MJ; Ross OA; Sharma M;
    Neurobiol Aging; 2017 Jan; 49():217.e1-217.e4. PubMed ID: 27814993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.